TY  - JOUR
PY  - 2023//
TI  - Prescription drugs with potential for misuse: protocol for a multi-indicator analysis of supply, detection and the associated health burden in Ireland between 2010 and 2020
JO  - BMJ open
A1  - Cousins, Gráinne
A1  - Durand, Louise
A1  - O'Kane, Aoife
A1  - Tierney, Julie
A1  - Maguire, Richard
A1  - Stokes, Siobhán
A1  - O'Reilly, Deirdre
A1  - Arensman, Ella
A1  - Bennett, Kathleen E.
A1  - Vázquez, María Otero
A1  - Corcoran, Paul
A1  - Lyons, Suzi
A1  - Kavanagh, Yvonne
A1  - Keenan, Eamon
SP  - e069665
EP  - e069665
VL  - 13
IS  - 3
N2  - INTRODUCTION: There is an increasing concern about the misuse of prescription drugs. Misuse refers to the intentional repurposing of prescribed drugs and/or the use of illicitly sourced prescription drugs, which may be counterfeit or contaminated. Drugs with the greatest potential for misuse are prescription opioids, gabapentinoids, benzodiazepines, Z-drugs and stimulants. <br><br>OBJECTIVE: The aim of this study is to provide a comprehensive analysis of the supply, patterns of use and health burden associated with prescription drugs with potential for misuse (PDPM) in Ireland between 2010 and 2020. Three inter-related studies will be carried out. The first study will describe trends in supply of PDPM using law enforcement drug seizures data and national prescription records from national community and prison settings. The second study aims to estimate trends in the detection of PDPM across multiple early warning systems using national forensic toxicology data. The third study aims to quantify the health burden associated with PDPM nationally, using epidemiological indicators of drug-poisoning deaths, non-fatal intentional drug overdose presentations to hospitals and drug treatment demand. <br><br>METHODS AND ANALYSIS: A retrospective observational study design, with repeated cross-sectional analyses, using negative binomial regression models or, where appropriate, joinpoint regression. ETHICS AND DISSEMINATION: The study has received approval from the RCSI Ethics Committee (REC202202020). <br><br>RESULTS will be disseminated in peer-reviewed journals, scientific and drug policy meetings and with key stakeholders via research briefs.<p />  <p>Language: en</p>
LA  - en
SN  - 2044-6055
UR  - http://dx.doi.org/10.1136/bmjopen-2022-069665
ID  - ref1
ER  -